Overview

Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients

Status:
Completed
Trial end date:
2017-09-14
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled study of single and multiple ascending doses of QR-010 in adults homozygous for ΔF508 Cystic Fibrosis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
ProQR Therapeutics
Collaborator:
European Commission